Hormone-like fibroblast growth factors and metabolic regulation

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 7, 2011, Pages 791-795

  Long, Yun Chau ^a   Kharitonenkov, Alexei ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Klotho; Klotho; Metabolic regulation

Indexed keywords

FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN;

BILE ACID METABOLISM; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; METABOLIC REGULATION; NONHUMAN; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REVIEW; VITAMIN D METABOLISM;

ANIMALS; FIBROBLAST GROWTH FACTORS; HORMONES; HUMANS;

EID: 79955590366     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.04.002     Document Type: Review

References (73)

1. Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res. 2010, 342:1-11.
2. Kharitonenkov A. FGFs and metabolism. Curr. Opin. Pharmacol. 2009, 9:805-810.
3. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., Ohyama Y., Kurabayashi M., Kaname T., Kume E., Iwasaki H., Iida A., Shiraki-Iida T., Nishikawa S., Nagai R., Nabeshima Y.I. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
4. Ito S., Kinoshita S., Shiraishi N., Nakagawa S., Sekine S., Fujimori T., Nabeshima Y.I. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech. Dev. 2000, 98:115-119.
5. Kharitonenkov A., Dunbar J.D., Bina H.A., Bright S., Moyers J.S., Zhang C., Ding L., Micanovic R., Mehrbod S.F., Knierman M.D., Hale J.E., Coskun T., Shanafelt A.B. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol. 2008, 215:1-7.
6. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K.P., Baum M.G., Schiavi S., Hu M.C., Moe O.W., Kuro-o M. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 2006, 281:6120-6123.
7. Lin B.C., Wang M., Blackmore C., Desnoyers L.R. Liver-specific activities of FGF19 require Klotho beta. J. Biol. Chem. 2007, 282:27277-27284.
8. Consortium ADHR Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 2000, 26:345-348.
9. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., Luo G., Jones S.A., Goodwin B., Richardson J.A., Gerard R.D., Repa J.J., Mangelsdorf D.J., Kliewer S.A. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005, 2:217-225.
10. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., Sandusky G.E., Hammond L.J., Moyers J.S., Owens R.A., Gromada J., Brozinick J.T., Hawkins E.D., Wroblewski V.J., Li D.S., Mehrbod F., Jaskunas S.R., Shanafelt A.B. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005, 115:1627-1635.
11. Nishimura T., Utsunomiya Y., Hoshikawa M., Ohuchi H., Itoh N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim. Biophys. Acta 1999, 1444:148-151.
12. Wu X., Ge H., Gupte J., Weiszmann J., Shimamoto G., Stevens J., Hawkins N., Lemon B., Shen W., Xu J., Veniant M.M., Li Y.S., Lindberg R., Chen J.L., Tian H., Li Y. Co-receptor requirements for fibroblast growth factor-19 signaling. J. Biol. Chem. 2007, 282:29069-29072.
13. Wu X., Lemon B., Li X., Gupte J., Weiszmann J., Stevens J., Hawkins N., Shen W., Lindberg R., Chen J.L., Tian H., Li Y. C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J. Biol. Chem. 2008, 283:33304-33309.
14. Xie M.H., Holcomb I., Deuel B., Dowd P., Huang A., Vagts A., Foster J., Liang J., Brush J., Gu Q., Hillan K., Goddard A., Gurney A.L. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999, 11:729-735.
15. Tomlinson E., Fu L., John L., Hultgren B., Huang X., Renz M., Stephan J.P., Tsai S.P., Powell-Braxton L., French D., Stewart T.A. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002, 143:1741-1747.
16. Fu L., John L.M., Adams S.H., Yu X.X., Tomlinson E., Renz M., Williams P.M., Soriano R., Corpuz R., Moffat B., Vandlen R., Simmons L., Foster J., Stephan J.P., Tsai S.P., Stewart T.A. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004, 145:2594-2603.
17. Tomiyama K., Maeda R., Urakawa I., Yamazaki Y., Tanaka T., Ito S., Nabeshima Y., Tomita T., Odori S., Hosoda K., Nakao K., Imura A. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc. Natl. Acad. Sci. USA 2010, 107:1666-1671.
18. Yu C., Wang F., Jin C., Huang X., McKeehan W.L. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J. Biol. Chem. 2005, 280:17707-17714.
19. Lundasen T., Galman C., Angelin B., Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J. Intern. Med. 2006, 260:530-536.
20. Huang X., Yang C., Luo Y., Jin C., Wang F., McKeehan W.L. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007, 56:2501-2510.
21. Wu X., Ge H., Lemon B., Weiszmann J., Gupte J., Hawkins N., Li X., Tang J., Lindberg R., Li Y. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc. Natl. Acad. Sci. USA 2009, 106:14379-14384.
22. Coskun T., Bina H.A., Schneider M.A., Dunbar J.D., Hu C.C., Chen Y., Moller D.E., Kharitonenkov A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
23. Nicholes K., Guillet S., Tomlinson E., Hillan K., Wright B., Frantz G.D., Pham T.A., Dillard-Telm L., Tsai S.P., Stephan J.P., Stinson J., Stewart T., French D.M. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 2002, 160:2295-2307.
24. Wu X., Ge H., Lemon B., Vonderfecht S., Weiszmann J., Hecht R., Gupte J., Hager T., Wang Z., Lindberg R., Li Y. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J. Biol. Chem. 2010, 285:5165-5170.
25. Izumiya Y., Bina H.A., Ouchi N., Akasaki Y., Kharitonenkov A., Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett. 2008, 582:3805-3810.
26. Nishimura T., Nakatake Y., Konishi M., Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 2000, 1492:203-206.
27. Wang H., Qiang L., Farmer S.R. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol. Cell. Biol. 2008, 28:188-200.
28. Wente W., Efanov A.M., Brenner M., Kharitonenkov A., Koster A., Sandusky G.E., Sewing S., Treinies I., Zitzer H., Gromada J. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006, 55:2470-2478.
29. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007, 5:426-437.
30. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., Li Y., Goetz R., Mohammadi M., Esser V., Elmquist J.K., Gerard R.D., Burgess S.C., Hammer R.E., Mangelsdorf D.J., Kliewer S.A. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5:415-425.
31. Uebanso T., Taketani Y., Fukaya M., Sato K., Takei Y., Sato T., Sawada N., Amo K., Harada N., Arai H., Yamamoto H., Takeda E. Hypocaloric high-protein diet improves fatty liver and hypertriglyceridemia in sucrose-fed obese rats via two pathways. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E76-E84.
32. Berglund E.D., Kang L., Lee-Young R.S., Hasenour C.M., Lustig D.G., Lynes S.E., Donahue E.P., Swift L.L., Charron M.J., Wasserman D.H. Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARalpha and FGF21 transcripts in vivo. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E607-E614.
33. Longuet C., Sinclair E.M., Maida A., Baggio L.L., Maziarz M., Charron M.J., Drucker D.J. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab. 2008, 8:359-371.
34. Potthoff M.J., Inagaki T., Satapati S., Ding X., He T., Goetz R., Mohammadi M., Finck B.N., Mangelsdorf D.J., Kliewer S.A., Burgess S.C. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. USA 2009, 106:10853-10858.
35. Badman M.K., Koester A., Flier J.S., Kharitonenkov A., Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009, 150:4931-4940.
36. Hotta Y., Nakamura H., Konishi M., Murata Y., Takagi H., Matsumura S., Inoue K., Fushiki T., Itoh N. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 2009, 150:4625-4633.
37. Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 2007, 282:26687-26695.
38. Ogawa Y., Kurosu H., Yamamoto M., Nandi A., Rosenblatt K.P., Goetz R., Eliseenkova A.V., Mohammadi M., Kuro-o M. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. USA 2007, 104:7432-7437.
39. Ding X., Peng L., Gerard R.D., Mangelsdorf D.J., Kliewer S.A. Beta-Klotho in adipose tissue is required for the anti-obesity effect of fibroblast growth factor 21 in mice. 40th Keystone Symposia, Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction (Jan 2011) Abstract 128 2011.
40. Chau M.D., Gao J., Yang Q., Wu Z., Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc. Natl. Acad. Sci. USA 2010, 107:12553-12558.
41. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M., Sivits G., Vonderfecht S., Hecht R., Li Y.S., Lindberg R.A., Chen J.L., Jung D.Y., Zhang Z., Ko H.J., Kim J.K., Veniant M.M. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
42. Johnson C.L., Weston J.Y., Chadi S.A., Fazio E.N., Huff M.W., Kharitonenkov A., Koester A., Pin C.L. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 2009, 137:1795-1804.
43. Arner P., Pettersson A., Mitchell P.J., Dunbar J.D., Kharitonenkov A., Ryden M. FGF21 attenuates lipolysis in human adipocytes-a possible link to improved insulin sensitivity. FEBS Lett. 2008, 582:1725-1730.
44. Galman C., Lundasen T., Kharitonenkov A., Bina H.A., Eriksson M., Hafstrom I., Dahlin M., Amark P., Angelin B., Rudling M. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 2008, 8:169-174.
45. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.F., Clutinger C.K., Tigno X.T., Hansen B.C., Shanafelt A.B., Etgen G.J. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
46. Berglund E.D., Li C.Y., Bina H.A., Lynes S.E., Michael M.D., Shanafelt A.B., Kharitonenkov A., Wasserman D.H. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009, 150:4084-4093.
47. Larsen P., Kharitonenkov A. FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol. Metab. 2010, 22:81-86.
48. Chen W.W., Li L., Yang G.Y., Li K., Qi X.Y., Zhu W., Tang Y., Liu H., Boden G. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 2008, 116:65-68.
49. Zhang X., Yeung D.C., Karpisek M., Stejskal D., Zhou Z.G., Liu F., Wong R.L., Chow W.S., Tso A.W., Lam K.S., Xu A. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
50. Fisher F.M., Chui P.C., Antonellis P.J., Bina H.A., Kharitonenkov A., Flier J.S., Maratos-Flier E. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010, 59:2781-2789.
51. Benet-Pages A., Orlik P., Strom T.M., Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 2005, 14:385-390.
52. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., Takeuchi Y., Fujita T., Nakahara K., Yamashita T., Fukumoto S. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 2002, 87:4957-4960.
53. Larsson T., Nisbeth U., Ljunggren O., Juppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003, 64:2272-2279.
54. Liu S., Zhou J., Tang W., Jiang X., Rowe D.W., Quarles L.D. Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E38-E49.
55. Riminucci M., Collins M.T., Fedarko N.S., Cherman N., Corsi A., White K.E., Waguespack S., Gupta A., Hannon T., Econs M.J., Bianco P., Gehron Robey P. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 2003, 112:683-692.
56. Bai X.Y., Miao D., Goltzman D., Karaplis A.C. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J. Biol. Chem. 2003, 278:9843-9849.
57. Larsson T., Marsell R., Schipani E., Ohlsson C., Ljunggren O., Tenenhouse H.S., Juppner H., Jonsson K.B. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004, 145:3087-3094.
58. Saito H., Kusano K., Kinosaki M., Ito H., Hirata M., Segawa H., Miyamoto K., Fukushima N. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J. Biol. Chem. 2003, 278:2206-2211.
59. Segawa H., Kawakami E., Kaneko I., Kuwahata M., Ito M., Kusano K., Saito H., Fukushima N., Miyamoto K. Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter. Pflugers Arch. 2003, 446:585-592.
60. Quarles L.D. Endocrine functions of bone in mineral metabolism regulation. J. Clin. Invest. 2008, 118:3820-3828.
61. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., Fukumoto S., Tomizuka K., Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 2004, 113:561-568.
62. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., Fujita T., Fukumoto S., Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
63. Nakatani T., Ohnishi M., Razzaque M.S. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J. 2009, 23:3702-3711.
64. Liu S., Vierthaler L., Tang W., Zhou J., Quarles L.D. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J. Am. Soc. Nephrol. 2008, 19:2342-2350.
65. Bai X., Miao D., Li J., Goltzman D., Karaplis A.C. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004, 145:5269-5279.
66. Brownstein C.A., Adler F., Nelson-Williams C., Iijima J., Li P., Imura A., Nabeshima Y., Reyes-Mugica M., Carpenter T.O., Lifton R.P. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc. Natl. Acad. Sci. USA 2008, 105:3455-3460.
67. Sitara D., Kim S., Razzaque M.S., Bergwitz C., Taguchi T., Schuler C., Erben R.G., Lanske B. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet. 2008, 4:e1000154.
68. Li S.A., Watanabe M., Yamada H., Nagai A., Kinuta M., Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct. Funct. 2004, 29:91-99.
69. Kharitonenkov A., Shanafelt A.B. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs 2008, 22:37-44.
70. Pai R., Dunlap D., Qing J., Mohtashemi I., Hotzel K., French D.M. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res. 2008, 68:5086-5095.
71. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
72. Yamazaki Y., Tamada T., Kasai N., Urakawa I., Aono Y., Hasegawa H., Fujita T., Kuroki R., Yamashita T., Fukumoto S., Shimada T. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J. Bone Miner. Res. 2008, 23:1509-1518.
73. Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., Smith K., Lee H., Thadhani R., Juppner H., Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008, 359:584-592.